Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan-Reference-Cited by-同舟云学术

Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan

Published:2024-08-10 Issue: Volume: Page:
ISSN:2193-8245
Container-title:Ophthalmology and Therapy
language:en
Short-container-title:Ophthalmol Ther

Author:

Yanagi Yasuo^ORCID,Takahashi Kanji,Iida Tomohiro,Gomi Fumi,Onishi Hiroshi,Morii Junko,Sakamoto Taiji

Funder

Senju Pharmaceutical Co., Ltd., Osaka, Japan.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40123-024-01011-z.pdf

Reference32 articles.

1. National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB). Quantity by drug class in NDB Open Data, Date of medical treatment: April 2021 to March 2022 injection medicine outpatient (in-hospital) (in Japanese) 2021. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000177221_00012.htmlAccessed 20 Dec 2023.

2. Chakraborty D, Mondal S, Boral S, et al. Biosimilar versus innovator molecule of ranibizumab in neovascular age-related macular degeneration (The BALANCE Trial): real-world evidence. Clin Ophthalmol. 2023;17:1067–76.

3. Loewenstein A, Czumbel N, Ernest J, Dusová J, Pearlman J, Nowosielska A. Randomized trial of biosimilar XSB-001 versus reference ranibizumab in patients with neovascular age-related macular degeneration. Ophthalmol Retina. 2023;7(9):753–61.

4. Bressler NM, Veith M, Hamouz J, et al. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. Br J Ophthalmol. 2023;107(3):384–91.

5. Holz FG, Oleksy P, Ricci F, et al. Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2022;129(1):54–63.